August 28, 2012 -- Inc. Magazine has named Frontage Laboratories to its sixth annual Inc. 5000, an exclusive ranking of the nation’s fastest-growing private companies. The 2012 list represents the most comprehensive look at the most important segment of the economy—America’s independent entrepreneurs. With a 3-year growth rate of 77%, Frontage joins VWR International, Quincy Bioscience, and Physicians’ Pharmaceutical, among other health care companies featured on this year’s list.
“Providing research services to the pharmaceutical industry has become more competitive and the economic climate is more challenging,” said Dr. Song Li, Chairman and CEO of Frontage. “Despite these hurdles, Frontage has experienced positive growth thanks to our continual focus on dependable quality, good service, and delivering projects on time and on budget.”
In a stagnant economic environment, median growth rate of 2012 Inc. 500|5000 companies remains an impressive 97%. The companies on this year’s list report having created over 400,000 jobs in the past three years, and aggregate revenue among the honorees reached $299 billion.
Among health care companies that made the list, Frontage ranked #239 and was #2,914 in the Inc. 5,000. Complete results, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/5000.
“Now, more than ever, we depend on Inc. 500/5000 companies to spur innovation, provide jobs, and drive the economy forward. Growth companies, not large corporations, are where the action is,” said Inc. Editor Eric Schurenberg when releasing the list Aug. 21. Methodology
The 2012 Inc. 500|5000 is ranked according to percentage revenue growth when comparing 2008 to 2011. To qualify, companies must have been founded and generating revenue by March 31, 2008. They had to be U.S.-based, privately held, for profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2011. (Since then, a number of companies on the list have gone public or been acquired.) The minimum revenue required for 2008 is $100,000; the minimum for 2011 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Companies on the Inc. 500 are featured in Inc.’s September issue. They represent the top tier of the Inc. 5000, which can be found at www.inc.com/500.
About Inc.
Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 6,000,000 today. For more information, visit www.inc.com.
About Frontage
Frontage Laboratories, Inc. is a global contract research, development and manufacturing organization, offering a full range of pharmaceutical R&D services. Frontage operates in the US and China, using one seamless GXP platform. Frontage runs four Phase I clinical research centers, an 88-bed unit in Hackensack, NJ; a 120-bed site in Zhengzhou, Henan Province China; 80 beds in Changchun, Jiling Province and 50 beds in Nanjing, Jiangsu Province, China. Frontage has an AAALAC certified Drug Metabolism and Pharmacokinetic facility in Pennsylvania, where it also maintains leading edge bioanalytical laboratories and separate CMC drug development and manufacturing facilities. In Shanghai and Beijing, China, the company also operates bioanalytical and CMC facilities. As a rapidly expanding CRO with ten years of successful GXP service offerings, Frontage has established an international standard in pharmaceutical product research, development, quality and management systems.
CONTACT:
Matt Harrington
Frontage Laboratories, Inc.
484.348.4772
mharrington@frontagelab.com
